DocDollars

Roche Molecular Systems, Inc.

CA · United States · Reporting entity ID 100000005630

Total reported 2019–2025
$65.5M
#139 of 2,960 reporting companies — 0.1% of all reported industry payments
$14.2M in general payments across 1,977 records, plus $51.3M in research funding across 3,084 records.

How it breaks down

General payments $14,169,903
Research funding $51,340,325

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Roche Molecular Systems, Inc. reported $65.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #139 of 2,960 reporting companies. 78% of that was research funding and 22% general payments such as consulting, speaking, food and travel. 1,977 general payment records and 3,084 research records were filed.

Common questions about Roche Molecular Systems, Inc.

How much has Roche Molecular Systems, Inc. paid US doctors?

Roche Molecular Systems, Inc. reported $65,510,228 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $14,169,903 in general payments, $51,340,325 in research funding.

How does Roche Molecular Systems, Inc. rank among drug and device companies?

It ranks #139 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Roche Molecular Systems, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.